ReviewCancer chemotherapy and pharmacology1996
Promising new agents in the treatment of non-small cell lung cancer.
Review in Cancer chemotherapy and pharmacology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 47 citations in OpenAlex.
- Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.Journal of clinical laboratory analysis · 2003Trial
- Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer.British journal of cancer · 1999Trial
- Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience.Investigational new drugsTrial
- Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.Scientific reports · 2017Article
- Article
- Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1).Journal of cellular and molecular medicine · 2010Article
- Oncolytic viral therapies.Cancer gene therapy · 2004Review
- Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress.British journal of cancer · 2003Article
- Selectively replicating viral vectors.Cancer gene therapy · 2002Review
- Anti-tumor efficacy of paclitaxel against human lung cancer xenografts.Japanese journal of cancer research : Gann · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.